Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| Cetuximab | Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor ( EGFR ), with a K d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: C225. CAS No. 205923-56-4. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-P9905. |  |
| Cetuximab | Cetuximab is a remarkable monoclonal antibody widely employed in the research of epidermal growth factor receptor (EGFR). Synonyms: N-(2-phenylethoxy)-1-pyridin-4-ylmethanimine; MLS002608064; AC1L5VKQ; CHEMBL1736329; MolPort-001-793-950; HMS3092B19. Grade: 95%. CAS No. 205923-56-4. Molecular formula: C6484H10042N1732O2023S36. Mole weight: 145KDa. |  |
| Cetuximab MMAE | Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity[1]. Uses: Scientific research. Group: Signaling pathways. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-171135. | |
| Cetuximab (PBS) | Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect[1]. Uses: Scientific research. Group: Inhibitory antibodies. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9S0008. | |
| EAI045 | EAI045 is an allosteric, non-ATP competitive inhibitor of mutant EGFR. In vitro studies proved that EAI045 is active and selective for T790M- harboring EGFR mutants that are in a monomer state. In vivo the combination of EAI045 and cetuximab caused a marked tumor shrinkage in a mouse model carrying the EGFR mutant with L858R/T790M/C797S. Therefore, EAI045 is the first allosteric inhibitor that targets T790M and C797S EGFR mutants but it is effective only in combination with cetuximab. Synonyms: 2-(5-fluoro-2-hydroxyphenyl)-2-(3-oxo-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide; 2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide; EAI045; EAI 045; EAI-045. CAS No. 1942114-09-1. Molecular formula: C19H14FN3O3S. Mole weight: 383.397. | |
| Fulzerasib | Fulzerasib (GFH925) is an irreversible KRAS G12C inhibitor, has a synergistic anti-cancer effect with cetuximab (HY-P9905). [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: IBI351; GFH925. CAS No. 2641747-54-6. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-152848. | |
| LDN-211904 oxalate | LDN-211904 oxalate is a potent and reversible EphB3 inhibitor with an IC50 of 79 nM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with Cetuximab (HY-P9905) could be effective in inhibiting STAT3-activated colorectal cancer (CRC) stemness and Cetuximab resistance in CRC[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1198408-78-4. Pack Sizes: 10 mM * 1 mL; 1 mg. Product ID: HY-107460. | |
| Patritumab | Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR , HER2 , HER3 , ERK , and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: Human Anti-ERBB3 Recombinant Antibody. CAS No. 1262787-83-6. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99275. | |
Our database is helping our users find suppliers everyday.
